Sessions

Development in Cell Therapy for Solid Tumours
What are the Cell and Gene Therapies of the Future?
Development in Neurology and Ophthalmology
Development in Stem Cell Therapeutics and Regenerative Medicine
Development in Cell & Gene Therapy to Treat Rare and Difficult Indications
Development for Non-Oncology Indications
Development in Allogeneic Cellular Therapies

Development in Cell Therapy for Solid Tumours

27 Jan 2022
15:30
SPONSORED BY
MilliporeSigma

15:30 Chairperson’s Opening
Christopher Ballas, Senior Vice President of Manufacturing, Innovative Cellular Therapeutics

15:35 Introducing the CoupledCAR Platform for Solid Tumor Therapy

  • Development of an indirect CAR approach
  • Experience with a multi-vector product
  • Early clinical experience

Christopher Ballas, Senior Vice President of Manufacturing, Innovative Cellular Therapeutics

15:50 Engineering Gamma Delta TCR for an Innovative Tumor Specific Cell Therapy

Mark Throsby, Chief Scientific Officer, Gadeta

16:05 Targeting Oncogenic Driver Mutations with TCR Therapies in Solid Tumors

  • Selection of TCRs to target oncogenic driver mutations
  • Engineering TCR therapies with immune modulatory fusion proteins (IFPs) and switches to overcome the tumor microenvironment
  • Gene editing approaches to optimize TCR therapies in solid tumors

Jak Knowles, Chief Executive Officer, Affini-T Therapeutics

16:20 Technical Solutions: Cell Therapies for Solid Tumors

  • Adapting known manufacturing paradigms to solid tumor-targeted therapeutics
  • Gene editing approaches for efficient tumor targeting
  • Moving with the industry, dynamics of technology development to meet market need

Nina Bauer, Director, Head of Commercial, Gene Editing and Novel Modalities, MilliporeSigma

16:35 Speaker Q&A and Panel Discussion

Speakers

Christopher Ballas
Senior Vice President, Manufacturing
Innovative Cellular Therapeutics
Mark Throsby
Chief Scientific Officer
Gadeta
Jak Knowles
Chief Executive Officer
Affini T
Nina Bauer
Senior Director, Head of Commercial, Gene Therapy
MilliporeSigma